Uncategorized

JFK Millennium Partners, the consortium leading a $4.2 billion redevelopment at JFK International Airport, has selected LOGIPIX US Corporation to implement an advanced Virtual Ramp Control System at the new JFK Terminal 6. This pioneering technology promises to revolutionize airport operations by enhancing security, efficiency, and safety on the ground. LOGIPIX, a global leader in …

Since its opening in 2020 in Richmond, Virginia, the Polykon Manufacturing LLC facility has strengthened Seppic’s proximity to our North American customers and expanded our manufacturing capabilities. Effective January 1, 2024, Polykon Manufacturing LLC took the next step by merging with its parent company, Seppic Inc. This change brings consistency to the organization of Seppic’s …

From the development of new medicines and cancer treatments to gene therapy and advances in scientific understanding of serious conditions such as Alzheimer’s disease, clinical research is helping drive the future of medical innovation and patient care. To further support that work, a coalition of health care systems, institutions of higher education, and other organizations …

Children’s National Hospital announced a $96 million investment from an anonymous donor family that strengthens its globally recognized leadership to transform rare childhood brain tumor research and care. It is one of the largest donations in the hospital’s history. It allows Children’s National to recruit more top talent and advance the most promising research for …

Johnson & Johnson Innovation, together with the Biomedical Advanced Research and Development Authority (BARDA), is proud to launch the BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen. Current and alumni Blue Knight residents and their collaborators are invited to submit promising potential pre-clinical or clinical solutions for the opportunity to receive award funding from a …

Recent global disease outbreaks have had devastating impacts, triggering a renewed emphasis on preparation for potential known and unknown health threats. By proactively enhancing preparedness against emerging pathogens, we aim to minimize the scale of future outbreaks, protect vulnerable populations, and ultimately safeguard our health security. To that end, Johnson & Johnson Innovation, together with …